Technology Partners

Technology Partners

Technology Partners was founded in 1983 in Palo Alto, California, by a group of scientists and engineers who believed venture capital should fund more than just software. The firm emerged from the era that produced the first wave of dedicated venture firms, but it carved a niche by insisting that its general partners hold advanced technical degrees and direct operating experience in industries like energy, materials, and life sciences. Roger Quy, a neuroscientist by training, joined the partnership and shaped its early identity around medical-device and diagnostics investing, while Ira Ehrenpreis would later become the firm's most visible face through an early and durable bet on electric vehicles. The firm deploys capital from its main venture funds across three primary domains: energy transition, life sciences, and advanced materials. Its energy practice, led by Ehrenpreis, includes a seed-stage investment in Tesla in 2006 that predated the company's IPO by four years — Ehrenpreis joined the Tesla board and remained a director for nearly two decades (per Bloomberg, 2023). Life sciences investments have produced exits spanning neurovascular devices, women's health, and molecular diagnostics, with portfolio company Concentric Medical acquired by Stryker for $135 million and SenoRx sold to C.R. Bard for over $200 million. The firm executes both early-stage and growth-stage deals, typically as a lead or co-lead, and writes initial checks between $5 million and $25 million. Its geographic focus remains overwhelmingly North American, though portfolio companies distribute globally. Technology Partners manages a series of venture funds that have historically raised between $150 million and $300 million apiece, maintaining what allocators describe as a disciplined fund-size model that avoids asset-gathering drift. The firm's partnership remains small and flat by design — fewer than a dozen investment professionals operate without a formal hierarchy of junior partners or associates pushing deal flow, a structure that concentrates sourcing in the GPs' own networks. In 2023, Ehrenpreis stepped down from the Tesla board after a 16-year tenure, a transition that refocused market attention on the firm's emerging energy-transition bets outside of Tesla, including advanced battery chemistry and carbon-capture technologies (per the firm, 2023). The firm does not operate a separate philanthropic foundation as a firmwide entity, though individual partners maintain independent charitable vehicles. Technology Partners functions less like a modern multistage platform and more like a research partnership that happens to write checks. Its GPs hold PhDs and MDs, not MBAs as a rule, and the firm's deal memos often read closer to scientific peer review than standard investment committee decks. This narrow aperture — deep science, concentrated portfolios, long holds — means the firm deliberately passes on entire sectors, including consumer internet and enterprise SaaS, that dominate the balance sheets of most Sand Hill Road peers. The organizational flatness removes a layer of discipline that conventional firms impose through internal promotion tracks, so succession turns on whether the next generation of scientist-investors can replicate the founder-GPs' proprietary access to university labs, government research programs, and founder-scientists who rarely take venture calls.